Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
McKinsey
AstraZeneca
Johnson and Johnson
Teva
Baxter
Covington
Harvard Business School
Medtronic

Generated: May 22, 2018

DrugPatentWatch Database Preview

Mivacurium chloride - Generic Drug Details

or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for mivacurium chloride and what is the scope of mivacurium chloride freedom to operate?

Mivacurium chloride
is the generic ingredient in three branded drugs marketed by Abbvie and Mylan Labs Ltd, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

There are two drug master file entries for mivacurium chloride. One supplier is listed for this compound.
Synonyms for mivacurium chloride
(1R,1'R)-2,2'-((((E)-oct-4-enedioyl)bis(oxy))bis(propane-3,1-diyl))bis(6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxybenzyl)-1,2,3,4-tetrahydroisoquinolin-2-ium) chloride
(1R)-2-(3-{[(4E)-8-{3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-2-ium-2-yl]propoxy}-8-oxooct-4-enoyl]oxy}propyl)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-1,
(R)-1,2,3,4-Tetrahydro-2-(3-hydroxypropyl)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxybenzyl)isoquinolinium chloride, (E)-4-octenedioate (2:1)
[R-[R*,R*-(E)]]2,2'-(1,8-Dioxo-4-octene-1,8-diyl)bis(oxy-3,1-propanediyl)bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinium] dichloride
106791-40-6
106861-44-3
133814-19-4
2,2'-[(1,8-Dioxo-4-octene-1,8-diyl)bis(oxy-3,1-propanediyl)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]isoquinolinium
791M406
861M443
AC1NQXXZ
AC1NQXZZ
AKOS025311198
AN-33846
AN-7609
bis[3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] (E)-oct-4-enedioate
bis[3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] (E)-oct-4-enedioate dichloride
BW B109OU dichloride
BW-B1090U
BW-B109OU
BW-B109OU DICHLORIDE
BWB109OU
C07550
C58H80Cl2N2O14
C58H80N2O14
CAS-106861-44-3
CAS-133814-19-4
CHEBI:6958
CHEBI:6959
CHEMBL1182833
CHEMBL984
Chlorure de mivacurium
Chlorure de mivacurium [French]
Cloruro de mivacurio
Cloruro de mivacurio [Spanish]
D00763
D0OB2M
DB01226
DSSTox_CID_26649
DSSTox_CID_28308
DSSTox_GSID_46649
DSSTox_GSID_48333
DSSTox_RID_81794
DSSTox_RID_82751
DTXSID5046649
DTXSID6048333
GTPL7243
Isoquinolinium, 2,2'-((1,8-dioxo-4-octene-1,8-diyl)bis(oxy-3,1-propanediyl))bis(1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-((3,4,5-trimethoxyphenyl)methyl)-, (1R-(1R*(E(1'R*))))-
Isoquinolinium, 2,2'-((1,8-dioxo-4-octene-1,8-diyl)bis(oxy-3,1-propanediyl))bis(1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-((3,4,5-trimethoxyphenyl)methyl)-, dichloride, (R-(R*,R*-(E)))-
LP066516
LS-172022
Mivacron
Mivacron (TN)
MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER
Mivacurii chloridum
Mivacurii chloridum [Latin]
Mivacurium
Mivacurium chloride (USAN/INN)
Mivacurium chloride [USAN:INN:BAN]
Mivacurium chloride(USAN/INN)
MolPort-023-220-239
NCGC00167469-01
NCGC00183094-01
SCHEMBL10014476
SCHEMBL10666657
SCHEMBL10666872
SCHEMBL41232
Tox21_112473
Tox21_112909

US Patents and Regulatory Information for mivacurium chloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie MIVACRON mivacurium chloride SOLUTION;INTRAVENOUS 020098-004 Jan 22, 1992 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Abbvie MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER mivacurium chloride INJECTABLE;INJECTION 020098-002 Jan 22, 1992 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Mylan Labs Ltd MIVACURIUM CHLORIDE mivacurium chloride INJECTABLE;INJECTION 078562-001 Apr 30, 2009 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Abbvie MIVACRON mivacurium chloride SOLUTION;INTRAVENOUS 020098-005 Jan 22, 1992 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for mivacurium chloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER mivacurium chloride INJECTABLE;INJECTION 020098-002 Jan 22, 1992 ➤ Sign Up ➤ Sign Up
Abbvie MIVACRON mivacurium chloride SOLUTION;INTRAVENOUS 020098-001 Jan 22, 1992 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Moodys
Baxter
Daiichi Sankyo
Cipla
Johnson and Johnson
US Army
Cerilliant
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.